Erector Spinae Plane Block in Congenital Heart Disease Patients
Congenital Heart Disease in Children, Neurologic Complication
About this trial
This is an interventional treatment trial for Congenital Heart Disease in Children focused on measuring Erector Spinae Plane Blockade, Pediatric Congenital Heart Disease
Eligibility Criteria
Inclusion Criteria:
- Neonates of at least 32 weeks of gestation, infants and children admitted to The Lucile Packard Children's Hospital for treatment of cyanotic or non-cyanotic heart disease requiring surgical intervention.
- Admitting diagnosis of cyanotic or non-cyanotic heart disease
Exclusion Criteria:
- Neonates less than 32 weeks of gestational age
- Any documented central nervous system malformations.
- Any potential subject requiring unexpected postoperative Extracorporeal membrane oxygenation (ECMO) support
Sites / Locations
Arms of the Study
Arm 1
Arm 2
No Intervention
Experimental
Volatile Anesthetic Control
Erector Spinae Plane Blockade Treatment
In volatile anesthetic technique, maintenance of anesthesia will be standardized to the volatile anesthetic isoflurane. Isoflurane will be delivered at 1.5-2.0%% as required for anesthetic management. Rocuronium or pancuronium will be used for muscle relaxation. Narcotic, fentanyl will be administered at no greater than 2 mcg/kg/hr. However, the primary anesthetic during CPB will be isoflurane with no narcotic administered during CPB.
Patients will receive an erector spinae plane blockade prior to their surgery as per standard regional anesthesia technique in addition to the standard of care Volatile Anesthetic Treatment.